JP2025539841A5 - - Google Patents

Info

Publication number
JP2025539841A5
JP2025539841A5 JP2025529969A JP2025529969A JP2025539841A5 JP 2025539841 A5 JP2025539841 A5 JP 2025539841A5 JP 2025529969 A JP2025529969 A JP 2025529969A JP 2025529969 A JP2025529969 A JP 2025529969A JP 2025539841 A5 JP2025539841 A5 JP 2025539841A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
sequence described
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025529969A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025539841A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/061813 external-priority patent/WO2024110905A1/en
Publication of JP2025539841A publication Critical patent/JP2025539841A/ja
Publication of JP2025539841A5 publication Critical patent/JP2025539841A5/ja
Pending legal-status Critical Current

Links

JP2025529969A 2022-11-24 2023-11-22 抗ｃｅａ抗体薬物コンジュゲート及びその使用方法 Pending JP2025539841A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/134067 2022-11-24
CN2022134067 2022-11-24
CNPCT/CN2023/107003 2023-07-12
CN2023107003 2023-07-12
PCT/IB2023/061813 WO2024110905A1 (en) 2022-11-24 2023-11-22 Anti-cea antibody drug conjugates and methods of use

Publications (2)

Publication Number Publication Date
JP2025539841A JP2025539841A (ja) 2025-12-09
JP2025539841A5 true JP2025539841A5 (enExample) 2026-02-18

Family

ID=88978400

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025529969A Pending JP2025539841A (ja) 2022-11-24 2023-11-22 抗ｃｅａ抗体薬物コンジュゲート及びその使用方法

Country Status (13)

Country Link
US (1) US20250115677A1 (enExample)
EP (1) EP4622677A1 (enExample)
JP (1) JP2025539841A (enExample)
KR (1) KR20250111207A (enExample)
CN (2) CN121177510A (enExample)
AR (1) AR131143A1 (enExample)
AU (1) AU2023383923A1 (enExample)
CL (1) CL2025001502A1 (enExample)
CO (1) CO2025008154A2 (enExample)
IL (1) IL320971A (enExample)
MX (1) MX2025006057A (enExample)
TW (1) TW202434306A (enExample)
WO (1) WO2024110905A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026511515A (ja) * 2023-03-23 2026-04-14 ビーワン メディシンズ ワン ゲーエムベーハー 生体活性コンジュゲートならびにその調製方法及びその使用
EP4735048A1 (en) * 2023-06-29 2026-05-06 Beone Medicines I GmbH Bioactive conjugates, preparation method and use thereof
CN121443323A (zh) * 2023-06-29 2026-01-30 广州百济神州生物制药有限公司 生物活性缀合物、其制备方法及用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
KR101981342B1 (ko) 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea 항체
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
EP3066470A4 (en) * 2013-11-05 2017-05-31 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
DK3107938T3 (da) 2014-05-28 2022-07-11 Zymeworks Inc Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
CN108283001B (zh) 2015-10-08 2022-08-19 酵活有限公司 包含κ和λ轻链的抗原结合多肽构建体及其用途
US20250122282A2 (en) * 2020-09-04 2025-04-17 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
CN117396182A (zh) * 2021-05-21 2024-01-12 百济神州有限公司 抗cea和抗cd137多特异性抗体及其使用方法
MX2024008036A (es) 2021-12-28 2024-07-15 Beigene Switzerland Gmbh Conjugados de anticuerpo y farmaco.

Similar Documents

Publication Publication Date Title
JP2020019787A5 (enExample)
JP2024059609A5 (enExample)
BR112021011014A2 (pt) Anticorpos anti-claudina e usos destes
JP2020509027A5 (enExample)
WO2021052402A1 (zh) 一种喜树碱衍生物及其偶联物
JP2017506234A5 (enExample)
JP2023547323A5 (enExample)
JP2010535713A5 (enExample)
JP2025523382A (ja) 抗ｂ７ｈ３抗体－薬物複合体及びその使用
JP2008526234A5 (enExample)
JP2020525542A5 (enExample)
JP2024501894A5 (enExample)
JP2012522513A5 (enExample)
EP3752534A1 (en) Glypican 3 antibodies and conjugates thereof
JP2017534256A5 (enExample)
CN107735093A (zh) Cd123抗体和其结合物
JP2017534253A5 (enExample)
RU2011144141A (ru) АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2025183307A5 (enExample)
JP2024533356A5 (enExample)
JP2017506630A5 (enExample)
JP5948525B1 (ja) 癌のための併用療法
RU2017112884A (ru) Иммуноконъюгаты, содержащие антитела против her2 и пирролбензодиазепины
JP2020500834A (ja) マクロファージ刺激タンパク質受容体（又はＲＯＮ（Ｒｅｃｅｐｔｅｕｒ ｄ′Ｏｒｉｇｉｎｅ Ｎａｎｔａｉｓ））抗体及びその使用
JP2024523422A (ja) 抗腫瘍化合物およびその応用